| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GBIO | Common Stock | Sale | -$791K | -30.6K | -14.17% | $25.89* | 185K | Sep 22, 2021 | Direct | F1, F2, F3 |
| transaction | GBIO | Common Stock | Sale | -$1.97M | -75.3K | -40.69% | $26.13* | 110K | Sep 23, 2021 | Direct | F1, F3, F4 |
| transaction | GBIO | Common Stock | Sale | -$27 | -1 | 0% | $26.55* | 110K | Sep 23, 2021 | Direct | F1, F3 |
| transaction | GBIO | Common Stock | Sale | -$746K | -28.9K | -26.29% | $25.84* | 80.9K | Sep 24, 2021 | Direct | F1, F3, F5 |
| transaction | GBIO | Common Stock | Sale | -$1.48K | -57 | -5.65% | $25.89* | 951 | Sep 22, 2021 | See footnote | F1, F2, F6 |
| transaction | GBIO | Common Stock | Sale | -$3.66K | -140 | -14.72% | $26.13* | 811 | Sep 23, 2021 | See footnote | F1, F4, F6 |
| transaction | GBIO | Common Stock | Sale | -$1.4K | -54 | -6.66% | $25.84* | 757 | Sep 24, 2021 | See footnote | F1, F4, F6 |
| holding | GBIO | Common Stock | 7.11M | Sep 22, 2021 | See footnote | F7 | |||||
| holding | GBIO | Common Stock | 1.17M | Sep 22, 2021 | See footnote | F8 |
| Id | Content |
|---|---|
| F1 | Shares were sold pursuant to a Rule 10b5-1 trading plan dated April 20, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.54 to $26.21 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2),(4) and (5). |
| F3 | The shares are held directly by Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP except to the extent of its pecuniary interest therein, if any. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.53 to $26.518 inclusive. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.40 to $26.21 inclusive. |
| F6 | The shares are held directly by Atlas Venture Associates Opportunity I, LP ("AVAO LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVAO LP except to the extent of its pecuniary interest therein, if any. |
| F7 | The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is AVA X LP. AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. |
| F8 | The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. |